2-(4-Chlorophenyl)-2,2-diphenylacetonitrile | 289887-40-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 2-(4-Chlorophenyl)-2,2-diphenylacetonitrile
• 英文别名: 2-(4-Chlorophenyl) 2,2-diphenylacetonitrile
• CAS: 289887-40-7
• 化学式: C₂₀H₁₄ClN
• 分子量: 303.791
• InChiKey: GMDAZDQAJNXESC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-chlorotrityl chloride 以 甲苯 为溶剂， 生成 2-(4-Chlorophenyl)-2,2-diphenylacetonitrile
  参考文献：
  名称：

  US6541494

  摘要：

  公开号：

文献信息

• Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
  申请人：The Regents of the University of California

  公开号：US07235577B1

  公开（公告）日：2007-06-26

  Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K+ channel (IKCa1) in lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-, cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Ca++ activated K+ channel (IKCa1) prevents the pre-Ca++ stage of cell activation and thus causes immunosuppression and an anti-inflammatory response.

  化合物、制剂和方法用于免疫抑制治疗自身免疫性疾病、移植排斥和/或移植/宿主病。通过给哺乳动物患者投予一定量的某些取代的三芳基甲烷化合物，例如1-[(2-氯苯基)二苯甲基]-1H-吡唑，选择性地抑制淋巴细胞、单核细胞、巨噬细胞、血小板或内皮细胞中的钙激活的K+通道（IKCa1），不会同时抑制P450依赖的酶系统，从而减少这些细胞通过储存激活钙通道的抗原、细胞因子或促进剂诱导的钙进入，抑制这些细胞的细胞因子产生，抑制这些细胞的激活。这种对Ca++激活的K+通道（IKCa1）的抑制防止了细胞激活的前Ca++阶段，从而引起免疫抑制和抗炎反应。
• Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls
  申请人：Koehler Ralf

  公开号：US20090048270A1

  公开（公告）日：2009-02-19

  Methods, compositions and devices for inhibiting neoproliferative changes in blood vessel walls or other anatomical structures. One or more compounds of Formula I or I-A set forth herein are administered systemically and/or locally to human or veterinary patients to deter or prevent unwanted proliferative changes in blood vessels or other anatomical structures. The invention may be used to deter or prevent stenosis or restenosis of arteries following angioplasty and/or stent placement. In one embodiment, there is provided an implantable stent or stent graft from which one or more compounds of the present invention will elute or otherwise be delivered into an affected blood vessel wall.

  本发明提供了抑制血管壁或其他解剖结构中新生增生的方法、组合物和装置。本发明中的公式I或I-A中的一个或多个化合物被系统性和/或局部地用于人类或兽医患者，以防止或预防血管或其他解剖结构中不必要的增生变化。本发明可用于防止或预防血管成形术和/或支架置入后的动脉狭窄或再狭窄。在一种实施方式中，提供了一种可植入的支架或支架移植物，其中本发明的一个或多个化合物将被释放或以其他方式输送到受影响的血管壁中。
• Methods for inhibiting neoproliferative changes in blood vessel walls
  申请人：The Regents of the University of California

  公开号：US08026263B2

  公开（公告）日：2011-09-27

  Methods, compositions and devices for inhibiting neoproliferative changes in blood vessel walls or other anatomical structures. One or more compounds of Formula I or I-A set forth herein are administered systemically and/or locally to human or veterinary patients to deter or prevent unwanted proliferative changes in blood vessels or other anatomical structures. The invention may be used to deter or prevent stenosis or restenosis of arteries following angioplasty and/or stent placement. In one embodiment, there is provided an implantable stent or stent graft from which one or more compounds of the present invention will elute or otherwise be delivered into an affected blood vessel wall.

  本发明涉及用于抑制血管壁或其他解剖结构的新生增殖变化的方法、组合物和装置。本发明中所述的公式I或I-A中的一个或多个化合物被系统和/或局部地用于人类或兽医患者，以防止或预防血管或其他解剖结构中不需要的增殖变化。本发明可用于防止或预防经过血管成形术和/或支架置入后的动脉狭窄或再狭窄。在一个实施例中，提供了一种可植入的支架或支架移植物，其中本发明的一个或多个化合物将被释放或以其他方式输送到受影响的血管壁中。
• NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO
  申请人：The Regents of The University of California

  公开号：EP1248614A2

  公开（公告）日：2002-10-16
• EP1248614A4
  申请人：——

  公开号：EP1248614A4

  公开（公告）日：2005-05-04